Arrowhead Pharmaceuticals is a dynamic biotech company based in Pasadena, California, that pioneers RNA interference (RNAi) therapies—innovative medicines designed to silence disease-causing genes with precision. Using its proprietary TRiM™ (Targeted RNAi Molecule) platform, the company develops treatments across a wide swath of therapeutic areas, including cardiometabolic disorders, liver and pulmonary diseases, and neuromuscular conditions. With a clear mission to fast-track drug development and bring transformative therapies to patients, Arrowhead is actively advancing an extensive pipeline, aiming to have up to 20 programs in clinical trials or on the market by 2025.